Reduced mucosal immunity to poliovirus after cessation of trivalent oral polio vaccine

References

• World Health Organization. Two out of three wild poliovirus strains eradicated. 2019 Oct 24 [accessed 2019 Oct 25]. https://www.who.int/news-room/feature-stories/detail/two-out-of-three-wild-poliovirus-strains-eradicated.
   Google Scholar
• Onorato IM, Modlin JF, McBean AM, Thoms ML, Losonsky GA, Bernier RH. Mucosal immunity induced by enhanced-potency inactivated and oral polio vaccines. J Infect Dis. 1991;163(1):1–6. doi:10.1093/infdis/163.1.1.
   PubMed Web of Science ®Google Scholar
• Laassri M, Lottenbach K, Belshe R, Wolff M, Rennels M, Plotkin S, Chumakov K. Effect of different vaccination schedules on excretion of oral poliovirus vaccine strains. J Infect Dis. 2005;192(12):2092–98. doi:10.1086/498172.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global eradication of wild poliovirus type 2 declared. 2015 Sep 20 [accessed 2015 Oct 6] http://www.polioeradication.org/mediaroom/newsstories/Global-eradication-of-wild-poliovirus-type-2-declared/tabid/526/news/1289/Default.aspx.
   Google Scholar
• Herremans MM, Van Loon AM, Reimerink JH, Rumke HC, Van Der Avoort HG, Kimman TG, Koopmans MP. Poliovirus-specific immunoglobulin A in persons vaccinated with inactivated poliovirus vaccine in The Netherlands. Clin Diagn Lab Immunol. 1997;4(5):499–503. doi:10.1128/CDLI.4.5.499-503.1997.
   PubMedGoogle Scholar
• Henry JL, Jaikaran ES, Davies JR, Tomlinson AJ, Mason PJ, Barnes JM, Beale AJ. A study of polio vaccination in infancy: excretion following challenge with live virus by children given killed or living poliovaccine. J Hyg (Lond). 1966;64(1):105–20. doi:10.1017/S0022172400040389.
   PubMedGoogle Scholar
• Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, Modlin JF, Patriarca PA, Sutter RW, Wright PF, et al. Expert review on poliovirus immunity and transmission. Risk Anal. 2013;33(4):544–605. doi:10.1111/j.1539-6924.2012.01864.x.
   PubMed Web of Science ®Google Scholar
• Hird TR, Grassly NC, Andino R. Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge. PLoS Pathog. 2012;8(4):e1002599. doi:10.1371/journal.ppat.1002599.
   PubMed Web of Science ®Google Scholar
• O’Ryan M, Bandyopadhyay AS, Villena R, Espinoza M, Novoa J, Weldon WC, Oberste MS, Self S, Borate BR, Asturias EJ, et al. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study. Lancet Infect Dis. 2015;15(11):1273–82. doi:10.1016/S1473-3099(15)00219-4.
   PubMed Web of Science ®Google Scholar
• Wright PF, Connor RI, Wieland-Alter WF, Hoen AG, Boesch AW, Ackerman ME, Oberste MS, Gast C, Brickley EB, Asturias EJ, et al. Vaccine-induced mucosal immunity to poliovirus: analysis of cohorts from an open-label, randomised controlled trial in Latin American infants. Lancet Infect Dis. 2016;16(12):1377–84. doi:10.1016/S1473-3099(16)30169-4.
   PubMed Web of Science ®Google Scholar
• Valtanen S, Roivainen M, Piirainen L, Stenvik M, Hovi T. Poliovirus-specific intestinal antibody responses coincide with decline of poliovirus excretion. J Infect Dis. 2000;182(1):1–5. doi:10.1086/315684.
   PubMed Web of Science ®Google Scholar
• Wright PF, Wieland-Alter W, Ilyushina NA, Hoen AG, Arita M, Boesch AW, Ackerman ME, Van Der Avoort H, Steven Oberste M, Pallansch MA, et al. Intestinal immunity is a determinant of clearance of poliovirus after oral vaccination. J Infect Dis. 2014;209(10):1628–34. doi:10.1093/infdis/jit671.
   PubMed Web of Science ®Google Scholar
• Resik S, Tejeda A, Mach O, Fonseca M, Diaz M, Alemany N, Heng Hung L, Aleman Y, Mesa I, Garcia G, et al. Does simultaneous administration of bivalent (types 1 and 3) oral poliovirus vaccine and inactivated poliovirus vaccine induce mucosal cross-immunity to poliovirus type 2? Clin Infect Dis. 2018;67(suppl_1):S51–S6. doi:10.1093/cid/ciy604.
   PubMedGoogle Scholar
• Sutter RW, Platt L, Mach O, Jafari H, Aylward RB. The new polio eradication end game: rationale and supporting evidence. J Infect Dis. 2014;210(Suppl 1):S434–8. doi:10.1093/infdis/jiu222.
   PubMedGoogle Scholar
• Thompson KM, Duintjer Tebbens RJ. Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes. BMC Infect Dis. 2015;15(1):374. doi:10.1186/s12879-015-1113-7.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Statement of the twenty-sixth polio IHR emergency committee. 2020 Oct 22 [accessed 2020 Oct 23] https://www.who.int/news/item/22-10-2020-statement-of-the-twenty-sixth-polio-ihr-emergency-committee.
   Google Scholar
• Garon J, Seib K, Orenstein WA, Ramirez Gonzalez A, Chang Blanc D, Zaffran M, Patel M. Polio endgame: the global switch from tOPV to bOPV. Expert Rev Vaccines. 2016;15(6):693–708. doi:10.1586/14760584.2016.1140041.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Statement of the twenty-second IHR emergency committee regarding the international spread of poliovirus. 2019 [accessed 2019 Oct 3]. https://www.who.int/news-room/detail/03-10-2019-statement-of-the-twenty-second-ihr-emergency-committee-regarding-the-international-spread-of-poliovirus.
   Google Scholar
• Nicoletta Previsani RHT, Graham T, Jafari HS. Guidelines for containment of poliovirus following type-specific polio eradication—worldwide. Morbidity and Mortality Weekly Report. 2015.
   Google Scholar
• Van Damme P, Coster I, Bandyopadhyay AS, Suykens L, Rudelsheim P, Neels P, Oberste MS, Weldon WC, Clemens R, Revets H, et al. Poliopolis: pushing boundaries of scientific innovations for disease eradication. Future Microbiol. 2019;14(15):1321–30. doi:10.2217/fmb-2019-0196.
   PubMed Web of Science ®Google Scholar
• De Coster I, Leroux-Roels I, Bandyopadhyay AS, Gast C, Withanage K, Steenackers K, De Smedt P, Aerssens A, Leroux-Roels G, Oberste MS, et al. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials. Lancet. 2021;397(10268):39–50. doi:10.1016/S0140-6736(20)32541-1.
   PubMed Web of Science ®Google Scholar
• Duintjer Tebbens RJ, Thompson KM. Evaluation of proactive and reactive strategies for polio eradication activities in Pakistan and Afghanistan. Risk Anal. 2019;39(2):389–401. doi:10.1111/risa.13194.
   PubMed Web of Science ®Google Scholar
• Thompson KM, Duintjer Tebbens RJ. Lessons from globally coordinated cessation of serotype 2 oral poliovirus vaccine for the remaining serotypes. J Infect Dis. 2017;216(suppl_1):S168–S75. doi:10.1093/infdis/jix128.
   PubMed Web of Science ®Google Scholar
• Kopel E, Kaliner E, Grotto I. Lessons from a public health Emergency — importation of wild poliovirus to Israel. N Engl J Med. 2014;371(11):981–83. doi:10.1056/NEJMp1406250.
   PubMed Web of Science ®Google Scholar
• Patriarca PA, Wright PF, John TJ. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis. 1991;13(5):926–39. doi:10.1093/clinids/13.5.926.
   PubMedGoogle Scholar
• Sutter RW, Cochi SL. Inactivated poliovirus vaccine supply shortage: is there light at the end of the tunnel? J Infect Dis. 2019;220(10):1545–46. doi:10.1093/infdis/jiy739.
   PubMed Web of Science ®Google Scholar
• Norton EB, Bauer DL, Weldon WC, Oberste MS, Lawson LB, Clements JD. The novel adjuvant dmLT promotes dose sparing, mucosal immunity and longevity of antibody responses to the inactivated polio vaccine in a murine model. Vaccine. 2015;33(16):1909–15. doi:10.1016/j.vaccine.2015.02.069.
   PubMed Web of Science ®Google Scholar